Agios Pharmaceuticals (AGIO) Stock Rating Reaffirmed by Goldman Sachs Group

Share on StockTwits

Goldman Sachs Group restated their neutral rating on shares of Agios Pharmaceuticals (NASDAQ:AGIO) in a research report sent to investors on Thursday morning, BenzingaRatingsTable reports. The firm currently has a $55.00 target price on the biopharmaceutical company’s stock.

A number of other research analysts have also recently commented on the company. Royal Bank of Canada increased their price target on Agios Pharmaceuticals to $90.00 in a research note on Thursday, May 16th. ValuEngine upgraded Agios Pharmaceuticals from a hold rating to a buy rating in a research note on Monday, April 1st. Cowen reiterated a buy rating on shares of Agios Pharmaceuticals in a research note on Wednesday, March 13th. BidaskClub upgraded Agios Pharmaceuticals from a hold rating to a buy rating in a research note on Friday, March 1st. Finally, Zacks Investment Research upgraded Agios Pharmaceuticals from a sell rating to a hold rating in a research note on Tuesday, February 12th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and seven have assigned a buy rating to the stock. The stock currently has an average rating of Hold and an average price target of $86.14.

NASDAQ AGIO opened at $48.33 on Thursday. The company has a debt-to-equity ratio of 0.11, a current ratio of 6.89 and a quick ratio of 6.86. Agios Pharmaceuticals has a fifty-two week low of $41.63 and a fifty-two week high of $99.82. The firm has a market cap of $2.84 billion, a price-to-earnings ratio of -8.01 and a beta of 2.25.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($1.59) earnings per share for the quarter, topping the consensus estimate of ($1.74) by $0.15. Agios Pharmaceuticals had a negative return on equity of 48.19% and a negative net margin of 300.63%. The firm had revenue of $30.20 million during the quarter, compared to analysts’ expectations of $22.69 million. During the same period in the prior year, the company earned ($1.63) earnings per share. The company’s quarterly revenue was up 243.2% on a year-over-year basis. As a group, analysts predict that Agios Pharmaceuticals will post -6.76 EPS for the current fiscal year.

In other news, insider Scott Biller sold 9,000 shares of the stock in a transaction on Wednesday, February 27th. The stock was sold at an average price of $65.00, for a total value of $585,000.00. Following the completion of the transaction, the insider now directly owns 28,277 shares in the company, valued at approximately $1,838,005. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Christopher Bowden sold 10,000 shares of the stock in a transaction on Monday, April 1st. The shares were sold at an average price of $66.57, for a total value of $665,700.00. Following the completion of the transaction, the insider now owns 17,238 shares of the company’s stock, valued at $1,147,533.66. The disclosure for this sale can be found here. Insiders sold a total of 42,000 shares of company stock valued at $2,765,530 over the last quarter. 3.16% of the stock is owned by corporate insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. ETF Managers Group LLC raised its position in Agios Pharmaceuticals by 15.7% during the 4th quarter. ETF Managers Group LLC now owns 1,592 shares of the biopharmaceutical company’s stock worth $73,000 after purchasing an additional 216 shares during the last quarter. Wealthstreet Investment Advisors LLC raised its position in Agios Pharmaceuticals by 0.9% during the 1st quarter. Wealthstreet Investment Advisors LLC now owns 29,415 shares of the biopharmaceutical company’s stock worth $1,984,000 after purchasing an additional 250 shares during the last quarter. Advisor Group Inc. raised its position in Agios Pharmaceuticals by 33.1% during the 4th quarter. Advisor Group Inc. now owns 1,195 shares of the biopharmaceutical company’s stock worth $55,000 after purchasing an additional 297 shares during the last quarter. California State Teachers Retirement System raised its position in Agios Pharmaceuticals by 0.4% during the 1st quarter. California State Teachers Retirement System now owns 80,018 shares of the biopharmaceutical company’s stock worth $5,396,000 after purchasing an additional 334 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its position in Agios Pharmaceuticals by 14.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,457 shares of the biopharmaceutical company’s stock worth $159,000 after purchasing an additional 430 shares during the last quarter.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc is a biopharmaceutical company, which engages in the discovery and development of novel investigational medicines to treat cancer and rare genetic diseases. It focuses on diseases that are directly caused by changes in genes or chromosomes, often passed from one generation to the next.

Read More: Support Level

Analyst Recommendations for Agios Pharmaceuticals (NASDAQ:AGIO)

Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Autoliv  PT Lowered to $62.00 at Buckingham Research
Autoliv PT Lowered to $62.00 at Buckingham Research
Shotspotter  Cut to “Market Perform” at Northland Securities
Shotspotter Cut to “Market Perform” at Northland Securities
Buckingham Research Increases Sonic Automotive  Price Target to $20.00
Buckingham Research Increases Sonic Automotive Price Target to $20.00
Vail Resorts  Earns Market Perform Rating from Analysts at Wells Fargo & Co
Vail Resorts Earns Market Perform Rating from Analysts at Wells Fargo & Co
Johnson Outdoors  Downgraded by Sidoti
Johnson Outdoors Downgraded by Sidoti
Autoliv  Stock Rating Upgraded by Robert W. Baird
Autoliv Stock Rating Upgraded by Robert W. Baird


© 2006-2019 Ticker Report